Novel inhibitor discovery against aromatase through virtual screening and molecular dynamic simulation: A computational approach in drug design

EXCLI Journal

Volumn 12, Issue , 2013, Pages 168-183

  Mirzaie, Sako ^a   Chupani, Latifeh ^b   Barzegari Asadabadi, Ebrahim ^b   Reza Shahverdi, Ahmad ^c   Jamalan, Mostafa ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Androstenedione; Aromatase; Aromatase inhibitor; Structural based virtual screening

Indexed keywords

ANDROSTENEDIONE; AROMATASE INHIBITOR;

ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; HYDROGEN BOND; HYDROPHOBICITY; MATHEMATICAL COMPUTING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; STRUCTURE ACTIVITY RELATION; VIRTUAL REALITY;

EID: 84875121613     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Abad-Zapatero C, Metz JT. Ligand efficiency indices as guideposts for drug discovery. Drug Discov Today 2005;10: 464-9.
2. Adlercreutz H. Phytoestrogens: epidemiology and a possible role in cancer protection. Environ Health Perspect 1995;103(Suppl 7):103-12.
3. Auclair K, Moenne-Loccoz P, Ortiz de Montellano PR. Roles of the proximal heme thiolate ligand in cytochrome p450(cam). J Am Chem Soc 2001;123:4877-85.
4. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H et al. The Protein Data Bank. Nucleic Acids Res 2000;28:235-42.
5. Berstein LM, Larionov AA, Pauley RJ, Chernitsa OI, Semiglazov VF, Yue W et al. Aromatase gene expression and its modifying factors in breast tumor tissue. Vopr Onkol 1999;45:504-10.
6. Bhatnagar AS. The discovery and mechanism of action of letrozole. Breast Cancer Res Treat 2007;105(Suppl 1):7-17.
7. Bonfield K, Amato E, Bankemper T, Agard H, Steller J, Keeler JM et al. Development of a new class of aromatase inhibitors: design, synthesis and inhibitory activity of 3-phenylchroman-4-one (isoflavanone) derivatives. Bioorg Med Chem 2012;20: 2603-13.
8. Buzdar AU. Role of aromatase inhibitors in advanced breast cancer. Endocr Relat Cancer 1999;6:219-25.
9. Cepa MM, Tavares da Silva EJ, Correia da Silva G, Roleira FM, Teixeira NA. Synthesis and biochemical studies of 17-substituted androst-3-enes and 3,4-epoxyandrostanes as aromatase inhibitors. Steroids 2008;73:1409-15
10. Chang MW, Ayeni C, Breuer S, Torbett BE. Virtual screening for HIV protease inhibitors: a comparison of AutoDock 4 and Vina. PLoS One 2010;5:e11955.
11. Chen S. Aromatase and breast cancer. Front Biosci 1998;3:d922-33.
12. Chen S, Zhou D. Functional domains of aromatase cytochrome P450 inferred from comparative analyses of amino acid sequences and substantiated by site-directed mutagenesis experiments. J Biol Chem 1992;267:22587-94.
13. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrineresponsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486-92.
14. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
15. Favia AD, Cavalli A, Masetti M, Carotti A, Recanatini M. Three-dimensional model of the human aromatase enzyme and density functional parameterization of the ironcontaining protoporphyrin IX for a molecular dynamics study of hemecysteinato cytochromes. Proteins 2006;62: 1074-87.
16. Goddard TD, Huang CC, Ferrin TE. Software extensions to UCSF chimera for interactive visualization of large molecular assemblies. Structure 2005;13:473-82.
17. Guengerich FP. Cytochrome P450: what have we learned and what are the future issues? Drug Metab Rev 2004;36:159-97.
18. Hamilton A, Volm M. Nonsteroidal and steroidal aromatase inhibitors in breast cancer. Oncology 2001;15:965-72; discussion 972, 977-969.
19. Hernandez BY, Green MD, Cassel KD, Pobutsky AM, Vu V, Wilkens LR. Preview of Hawaii cancer facts and figures 2010. Hawaii Med J 2010;69:223-4.
20. Hong Y, Yu B, Sherman M, Yuan YC, Zhou D, Chen S. Molecular basis for the aromatization reaction and exemestanemediated irreversible inhibition of human aromatase. Mol Endocrinol 2007;21:401-14.
21. Hong Y, Rashid R, Chen S. Binding features of steroidal and nonsteroidal inhibitors. Steroids 2011;76:802-6.
22. Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov Today 2004;9:430-1.
23. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996;14:33-8, 27-38.
24. Ibrahim AR, Abul-Hajj YJ. Aromatase inhibition by flavonoids. J Steroid Biochem Mol Biol 1990;37:257-60.
25. Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: a free tool to discover chemistry for biology. J Chem Inf Model 2012 Jun 15 [Epub ahead of print]
26. Jeong HJ, Shin YG, Kim IH, Pezzuto JM. Inhibition of aromatase activity by flavonoids. Arch Pharm Res 1999;22:309-12.
27. Kao YC, Cam LL, Laughton CA, Zhou D, Chen S. Binding characteristics of seven inhibitors of human aromatase: a sitedirected mutagenesis study. Cancer Res 1996;56:3451-60.
28. Kao YC, Zhou C, Sherman M, Laughton CA, Chen S. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: a site-directed mutagenesis study. Environ Health Perspect 1998;106: 85-92.
29. Karkola S, Wahala K. The binding of lignans, flavonoids and coumestrol to CYP450 aromatase: a molecular modelling study. Mol Cell Endocrinol 2009;301:235-44.
30. Kellis JT Jr, Vickery LE. Inhibition of human estrogen synthetase (aromatase) by flavones. Science 1984;225:1032-4.
31. Kellis JT Jr, Nesnow S, Vickery LE. Inhibition of aromatase cytochrome P-450 (estrogen synthetase) by derivatives of alpha-naphthoflavone. Biochem Pharmacol 1986;35:2887-91.
32. Kellis JT Jr, Childers WE, Robinson CH, Vickery LE. Inhibition of aromatase cytochrome P-450 by 10-oxirane and 10-thiirane substituted androgens: implications for the structure of the active site. J Biol Chem 1987;262:4421-6.
33. Kiely M, Faughnan M, Wahala K, Brants H, Mulligan A. Phyto-oestrogen levels in foods: the design and construction of the VENUS database. Br J Nutr 2003;89(Suppl 1):S19-23.
34. Laskowski RA, Swindells MB. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 2011;51:2778-86.
35. Locker GY, Mansel R, Cella D, Dobrez D, Sorensen S, Gandhi SK. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat 2007;106:229-38.
36. Mazur WM, Uehara M, Wahala K, Adlercreutz H. Phyto-oestrogen content of berries, and plasma concentrations and urinary excretion of enterolactone after a single strawberry-meal in human subjects. Br J Nutr 2000;83:381-7.
37. Meunier B, de Visser SP, Shaik S. Mechanism of oxidation reactions catalyzed by cytochrome p450 enzymes. Chem Rev 2004;104:3947-80.
38. Milder IE, Arts IC, Venema DP, Lasaroms JJ, Wahala K, Hollman PC. Optimization of a liquid chromatography-tandem mass spectrometry method for quantification of the plant lignans secoisolariciresinol, matairesinol, lariciresinol, and pinoresinol in foods. J Agric Food Chem 2004;52: 4643-51.
39. Miller WR. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr Relat Cancer 1999;6:187-95.
40. Miller WR, Bartlett J, Brodie AM, Brueggemeier RW, di Salle E, Lonning PE et al. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 2008;13:829-37.
41. Sakamoto T, Horiguchi H, Oguma E, Kayama F. Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor-positive breast cancer cells. J Nutr Biochem 2010; 21:856-64.
42. Sandeep G, Nagasree KP, Hanisha M, Kumar MM. AUDocker LE: A GUI for virtual screening with AUTODOCK Vina. BMC Res Notes 2011;4:445.
43. Santen RJ, Harvey HA. Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer 1999;6:75-92.
44. Santen RJ, Manni A, Harvey H, Redmond C. Endocrine treatment of breast cancer in women. Endocr Rev 1990;11:221-65.
45. Santen RJ, Yue W, Naftolin F, Mor G, Berstein L. The potential of aromatase inhibitors in breast cancer prevention. Endocr Relat Cancer 1999;6:235-43.
46. Schuttelkopf AW, van Aalten DM. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 2004;60:1355-63.
47. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994;15:342-55.
48. Takahashi M, Yamashita K, Numazawa M. Probing the binding pocket of the active site of aromatase with 2-phenylaliphatic androsta-1,4-diene-3,17-dione steroids. Steroids 2010;75:330-7.
49. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31:455-61.
50. van der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: fast, flexible, and free. J Comput Chem 2005;26:1701-18.
51. Williams PA, Cosme J, Sridhar V, Johnson EF, McRee DE. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 2000;5:121-31.
52. Yadav MR, Sabale PM, Giridhar R, Zimmer C, Haupenthal J, Hartmann RW. Synthesis of some novel androstanes as potential aromatase inhibitors. Steroids 2011;76:464-70.